“During the third quarter, our team continued to advance our portfolio while winding down activities surrounding the BEACON-IPF trial,” said Bernard Coulie, President and Chief Executive Officer of Pliant. “Looking ahead, we continue to evaluate a range of opportunities to create shareholder value.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Announces CBO Hans Hull’s Resignation
- Pliant Therapeutics Settles Loan with Oxford Finance
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan